CAR-T for Autoimmunity: Bluestone Joins Sonoma Biotherapeutics, a $40M Bet

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

T Cell Therapies for Autoimmunity: Jeff Bluestone on The Long Run
Sonoma Bio, Engineering T-cell Therapies for Autoimmunity, Nabs $265M Series B